INTRODUCTION
Macrophages, as innate immune competent cells, participate in a multitude of physiological as well as patho-physiological settings, which is a result of their extreme functional plasticity. Distinct forms of macrophage activation provoke a continuum of functional responses that range from pro-towards anti-inflammatory outcomes. Macrophages are classically activated by microbial cell wall components and/or IFN-. The resulting phenotype is known as M1, which is characterized among others parameters by the production of pro-inflammatory mediators such as NO, superoxide, TNF-, IL-1 and IL-6 (Gordon, 2003) . Polarization towards the alternatively activated phenotype (M2 macrophage) is achieved by e.g. glucocorticoids, IL-4, IL-13 or IL-10 ( Mantovani et al., 2002; Gordon, 2003) .
When cells enter the route of apoptotic cell death, phagocytosis of apoptotic debris by professional phagocytes such as macrophages avoids an inflammatory response (Rathmell and Thompson, 1999; Savill et al., 2002) . During this process the interaction of apoptotic cells (AC) with macrophages actively suppresses the release of pro-inflammatory mediators and provokes the formation of anti-inflammatory ones.
The mediator profile of these polarized macrophages resembles those of M2 cells, with the production of e.g. IL-10, TGF-1 or PGE 2 (Voll et al., 1997; Fadok et al., 1998; Freire-de-Lima et al., 2000) . Mechanisms attenuating pro-inflammatory signaling in macrophages by AC are at least in part attributed to defective LPSinduced NF-B activation, and thus inhibition of pro-inflammatory cytokine gene expression profiles (Cvetanovic and Ucker, 2004) .
In contrast, intracellular pathways activating anti-inflammatory responses are widely elusive. Recently, we observed that AC released the bioactive lipid sphingosine-1-5 phosphate (S1P), which caused activation of survival pathways such as increased expression of the anti-apoptotic proteins Bcl-2 and Bcl-X L in human macrophages (Weigert et al., 2006) . Although pioneering studies identified S1P as a second messenger molecule mediating cell proliferation of Swiss 3T3 fibroblasts (Olivera and Spiegel, 1993) , S1P was later identified as the ligand for a family of five different G protein-coupled receptors (Hla et al., 2001; Taha et al., 2004) . Activation of S1P receptors exerts a powerful influence on a variety of immune cells and their responses (von Wenckstern et al., 2006) . Moreover, S1P provoked M2 macrophage polarization either when added directly to cells (Hughes et al., 2008) , or when being present in the supernatant of AC (Weigert et al., 2007 ).
An ideal candidate that would fulfill requirements of acting anti-inflammatory as well as anti-apoptotic is heme oxygenase-1 (HO-1). HO-1 catalyzes the rate-limiting step in the oxidative degradation of heme to equimolar quantities of biliverdin, ferrous iron and carbon monoxide (CO). In contrast to HO-2 and HO-3, which are constitutively expressed, HO-1 is inducible and is well known to protect from cell death, i.e. apoptosis, inflammation and oxidative stress in vivo (Otterbein et al., 2000; Deshane et al., 2005; Kim et al., 2006) . A connection between HO-1 induction and the S1P-pathway was recently established in a model of hepatic ischemia-reperfusion injury, where the S1P receptor agonist FTY720 enhanced HO-1 expression in hepatocytes (Man et al., 2005) .
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MATERIALS AND METHODS
Cell culture and reagents
Jurkat T cells were maintained in RPMI 1640, supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin and 10% heat-inactivated FCS (PAA Laboratories, Cölbe, Germany). SB203580 was obtained from Alexis (Lörrach, Germany), the Janus kinase (Jak) inhibitor I was purchased from Calbiochem (Darmstadt, Germany), S1P came from Avanti (Alabaster, AL, USA), fludarabine was obtained from Sigma-Aldrich (Steinheim, Germany), STA-21 was delivered by Biomol (Hamburg, Germany), Deta-NO, bilirubin and tricarbonyldichloro ruthenium (II) dimer (CORM-2) were obtained from Sigma-Aldrich (Steinheim, Germany). CORM-2 was freshly dissolved in DMSO for each experiment. As a negative control, CORM-2 was inactivated (iCORM-2) according to a previously described method (Sun et al., 2008) . Trypan blue staining (Biochrom AG, Berlin, Germany) revealed that all used reagents were not toxic for macrophages.
Human monocyte isolation and culture
Human monocytes were isolated as described previously (Weigert et al., 2006) . In brief, using Ficoll-Hypaque gradients (PAA Laboratories, Cölbe, Germany) monocytes were isolated from buffy coats (DRK-Blutspendedienst BadenWürttemberg-Hessen, Institut für Transfusionsmedizin und Immunhämatologie Frankfurt am Main, Frankfurt/Main, Germany). Peripheral blood mononuclear cells were washed twice with PBS containing 2 mM EDTA and subsequently incubated for 1 h at 37°C in RPMI 1640 supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin to allow their adherence to culture dishes (Sarstedt, Nümbrecht, Germany). After removing nonadherent cells, monocytes were differentiated to macrophages with RPMI containing 10% ABpositive human plasma (DRKBlutspendedienst Baden-Württemberg-Hessen, Institut für Transfusionsmedizin und Immunhämatologie Frankfurt am Main, Frankfurt/Main, Germany) for 7 days.
Generation of conditioned media
Apoptosis in Jurkat cells, cultured in RPMI 1640 without FCS, was induced with 0.5 µg/mL staurosporine (Sigma-Aldrich, Steinheim, Germany) for 3 h (Weigert et al., 2006) . Necrotic Jurkat cells were generated by incubating cells for 30 min at 56°C in RPMI 1640 with FCS (Weigert et al., 2006) . AC or necrotic cells (NC) were washed twice with PBS and incubated for another 3-h period in RPMI 1640 with 10% ABpositive human plasma. CM was harvested by centrifugation (1000 g, 10 minutes) and filtration through 0.22 µm pore filters (Millipore, Schwalbach, Germany) to remove apoptotic bodies. The procedure to generate CM from viable cells (VC) was equivalent. Jurkat cells were incubated in RPMI 1640 with FCS, omitting a death stimulus. To obtain AC-CM without S1P, we used 20 µM dimethylsphingosine (DMS, Biomol, Hamburg, Germany), an inhibitor of sphingosine kinases. DMS was added simultaneously with staurosporine to Jurkat cells during initiation of apoptosis (Weigert et al., 2006) . To generate macrophage CM (MФ-CM), macrophages were incubated with AC-CM for 2 h, washed twice with PBS and incubated for another 4-h period in RPMI 1640 with 10% ABpositive human plasma. MФ-CM was harvested by centrifugation (1000 g, 10 minutes). For protein degradation, MФ-CM was incubated with 50 µg/mL proteinase K (Sigma-Aldrich, Steinheim, Germany) at 37°C for 1 h, followed by incubation at 100°C for 1 h. Cells were exposed to conditioned media for the times indicated. Inhibitors were pre-incubated for 1 h each. CM was generated using 1 x 10 7 Jurkat cells and later on added to 2 x 10 6 macrophages (ratio 5:1). MФ-CM was directly transferred from generator to recipient cells.
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Western blot analysis
Western blot analysis was performed as previously described (von Knethen et al., 2005 
RNA extraction and quantitative real-time PCR
RNA from primary human macrophages was extracted using peqGold RNAPure 
Reporter analysis
Reporter assays were performed with vector constructs containing 4000 bp, 2782 bp or 1976 bp of the human HO-1 promoter fused to a firefly luciferase gene (Takahashi et al., 1999) . The STAT3 point mutation was created with the Quik Change II SiteDirected Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Experimentally, 10% of one buffy coat monocyte isolation preparation was seeded in one 12-well plate. After 7 days macrophages were co-transfected with HO-1 promoter constructs and renilla luciferase control vector pRL-CMV (Promega, Mannheim, Germany) using Jet Pei transfection reagent (Polyplus transfection, Illkirch, France). After transfection, cells
were incubated for 24 h, medium was changed and cells were incubated for another 24 h followed by individual stimulation. Firefly luciferase activity normalized to renilla luciferase activity was determined after 18-h incubations with MФ-CM or after 24 h following incubations with 100 nM S1P.
Site-directed mutagenesis
The online tool TFSearch (http://www.cbrc.jp/research/db/TFSEARCH.html) was used to identify potential STAT binding sites in the human HO-1 promoter (STATx).
Quik Change II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used to introduce a point mutation of the putative STAT-binding site at position -2361 to -2369 within the human HO-1 promoter, in order to impair STAT3 binding.
The following primers (Biomers, Ulm, Germany) were used to mutate the sequence from 5'-TTC CAG GAA-3' to 5'-TTC CAG GCC-3': 5'-CCA GGC ACT ATT CCA GGC CCT GGG AAT TTA CAA AGC-3', 5'-GCT TTG TAA ATT CCC AGG GCC TGG AAT AGT GCC TGG-3'. Elongation was performed at 68°C for 15 min. Site-directed mutagenesis was confirmed by sequencing (Agowa, Berlin, Germany).
Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared as previously described (Von Knethen and Brune, 2001 ) and an established electrophoretic mobility shift assay (EMSA) method (Weigert et al., 2007) 
Statistical analysis
Each experiment was performed at least three times. P-values were calculated using the paired Student t test and considered significant (*) at P  0.05, (**) at P  0.01 and (***) at P  0.001.
RESULTS
Apoptotic cell supernatants provoke a biphasic upregulation of HO-1
In a first set of experiments, we analyzed HO-1 protein expression in primary human macrophages following their exposure to AC-CM. HO-1 expression showed a biphasic response. A first peak was noticed after 6 h, whereas a second peak became detectable after 24-h lasting incubations ( Figure 1A ). To test whether the second peak of HO-1 expression was mediated by an autocrine factor, we harvested supernatants from macrophages (MФ-CM), previously stimulated with AC-CM, and Induction of HO-1 by MФ-CM after 18 h was further corroborated by reporter assays.
Using the luciferase-coupled promoter constructs phHOLUC(-4000) as well as phHOLUC(-2782), we observed significant induction of luciferase activity after treatment with MФ-CM for 18 h ( Figure 1D ). No activity was noticed with the shorter luciferase construct phHOLUC (-1976) . Results so far indicate that apoptotic cell supernatants enhanced not only transcription of the HO-1 promoter but also caused protein expression, with the further notion that autocrine signaling was involved.
We then investigated signal transduction pathways contributing to HO-1 expression.
Early expression of HO-1, seen at 6 h in response to AC-CM, was reduced by SB203580, an inhibitor of p38 MAPK ( Figure 1E ). Late phase HO-1 expression at 24 h was partially attenuated by inhibiting janus kinase signaling ( Figure 1F ). Thus, the early HO-1 induction in response to an AC-CM-derived soluble factor was p38-mediated, while the late and second phase of HO-1 expression was facilitated by an autocrine factor, signaling via the Jak pathway.
S1P in AC-CM is crucial in provoking HO-1 induction
Considering that AC release S1P (Weigert et al., 2006; Gude et al., 2008) and the further notion that S1P potentially causes HO-1 expression (Man et al., 2005) , we assumed that S1P in AC-CM was responsible for HO-1 expression in macrophages.
To verify this hypothesis, we stimulated primary human macrophages with authentic S1P for 24 h ( Figure 2A ). S1P at 100 nM and 1 µM as well as AC-CM induced HO-1 protein expression. To validate the contribution of S1P in AC-CM, we used DMS, an inhibitor of sphingosine kinases to block their activity in Jurkat cells when generating AC-CM (Weigert et al., 2006) . AC-CM generated in the presence of DMS failed in inducing HO-1 expression in macrophages ( Figure 2A ). Supporting data pointing to the contribution of S1P in HO-1 expression came from experiments when 100 nM S1P, supplied for 24 h, induced luciferase reporter activity. S1P induced phHOLUC(-4000) and phHOLUC(-2782) but not phHOLUC (-1976 ) HO-1 reporter activity ( Figure   2B ).
Recently, it was reported that activation of S1P 1 limited the expression of proinflammatory cytokines (Hughes et al., 2008) and protected macrophages from apoptosis induced by the combination of TNF and cycloheximide (Weigert et al., 2006) . Intrigued by these experiments, we knocked down S1P 1 using siRNA to assess its role in HO-1 induction by AC-CM. While transfection of macrophages with nontargeting siRNA allowed HO-1 expression by AC-CM after 6 h, knockdown of S1P 1 significantly reduced the HO-1 amount ( Figure 2C ). As a side effect, we noticed 14 that AC-CM enhanced S1P 1 expression in primary human macrophages, an effect suppressed by siRNA directed against S1P 1 ( Figure 2C ).
STAT1 and STAT3 provoke transcription of the HO-1 gene after AC-CM
The induction of HO-1 after 24 h was Jak dependent ( Figure 1F ). Considering that HO-1 induction at 24 h was facilitated by an autocrine factor, we wished to discern whether the release or the action of the putative autocrine factor would be Jak dependent. Therefore, we analyzed signaling downstream of janus kinases, by using STAT1 and STAT3 inhibitors.
To attenuate the release of autocrine mediators, macrophages were pre-incubated for 1 h with either fludarabine, a specific inhibitor of STAT1 (Frank et al., 1999) , or STA-21, a specific STAT3 inhibitor (Song et al., 2005) , prior to addition of AC-CM. Figure 3E ). STAT binding to the oligonucleotides containing the STAT binding site at -2361 to -2369 was strongly reduced with increasing concentrations of the specific STAT1 and STAT3 oligonucleotides, which were added simultaneously.
In contrast STAT binding was not impaired when we used oligonucleotides with the STAT3 point mutation. In addition, we performed reporter assays in primary human macrophages with the construct phHOLUC(-2782ptm). This construct contained a point mutation within the STAT binding site at -2361 to -2369 to eliminate STAT3 binding ( Figure 3F ). Transfection of this construct into macrophages confirmed the 16 results obtained by EMSA analysis, since luciferase activity elicited by MФ-CM was significantly lower compared to transfection of the non-mutated phHOLUC(-2782).
Late-phase HO-1 induction in macrophages requires autocrine VEGFA signaling
With the following experiments we characterized the autocrine HO-1-inducing factor, released by macrophages, when treated with AC-CM. We degraded proteins in MФ-CM with proteinase K digestion and subsequent denaturation. MФ-CM, deprived by functional proteins, revealed a significantly lower ability to express HO-1 compared to untreated MФ-CM ( Figure 4A ), implying that the autocrine factor might be a protein.
As a candidate we proposed VEGF. Our previous results ( Figure 3A ) suggested that the release of the autocrine factor mediating HO-1 induction was STAT1-dependent.
This corresponds to the observations of Funamoto and colleagues, who identified
VEGF as a STAT1 target gene in cardiac myocytes (Funamoto et al., 2000) .
Furthermore, VEGFA secretion from mouse mammary epithelial cells after phagocytosis of AC was previously demonstrated (Golpon et al., 2004) and signaling of VEGF in chronic lymphocytic leukaemia B cells enhanced STAT1 and STAT3
actions . These observations match our data, showing that the autocrine protein factor in MФ-CM activated STAT1/STAT3 (Figure 3, A and B) .
Finally, VEGF induced HO-1 in a model of hyperoxic acute lung injury (Siner et al., 2007) . With this background we determined VEGF expression in macrophages in response to AC-CM. Indeed, VEGF mRNA was significantly elevated in macrophages stimulated with AC-CM for 1 h, compared to controls. Elevation of VEGF mRNA was blocked when macrophages were pre-treated with fludarabine ( Figure 4B ). Additionally, we measured the release of VEGF into supernatants of AC-CM treated macrophages by FACS analysis using human VEGF Cytometric Bead Array Flex Sets ( Figure 4C ). AC-CM-stimulated macrophages secreted significant amounts of VEGF protein. Accompanying experiments confirmed that 100 nM authentic S1P, incubated for 1 h, enhanced VEGF mRNA expression, thus supporting the notion that S1P in AC-CM may induce VEGF ( Figure 4D ). The fact that HO-1 as well as VEGF expression were induced by S1P (Figures 2A and 4D ), made the induction of HO-1 by autocrine VEGF signaling in primary human macrophages likely. To further scrutinize this hypothesis, we knocked down VEGF in primary human macrophages prior to their incubation with AC-CM ( Figure 4E ). While VEGF mRNA was induced in macrophages after treatment with AC-CM, the response was abrogated by siRNA directed towards VEGFA ( Figure 4E ). Next, we analyzed the expression of HO-1 protein in macrophages, which were incubated with MФ-CM generated from VEGF knockdown or siControl transfected macrophages.
When macrophages were transfected with non-targeting siRNA and incubated with AC-CM, MФ-CM derived from these cells induced HO-1 in fresh, unstimulated cells.
However, HO-1 was not induced with MФ-CM from VEGFA knockdown macrophages ( Figure 4F ). These experiments suggest that VEGF mediated the autocrine induction of HO-1 after stimulation with AC-CM.
HO-1 affects anti-inflammatory and anti-apoptotic pathways in macrophages
HO-1 is known for its anti-apoptotic and anti-inflammatory actions (Otterbein et al., 2000; Ryter and Otterbein, 2004; Deshane et al., 2005) . Having recently shown that S1P from AC-CM induced Bcl-2 and Bcl-X L in macrophages (Weigert et al., 2006) , we now asked whether induction of Bcl-2 and/or Bcl-X L required HO-1.
Experimentally, we knocked down HO-1 in primary human macrophages using siRNA technology. Transfection with siRNA directed against HO-1 efficiently blocked the mRNA increase of HO-1 after treatment with AC-CM for 9 h ( Figure 5A ). While AC-CM upregulated Bcl-2 and Bcl-X L mRNA in macrophages transfected with nontargeting siRNA, induction was significantly diminished when macrophages were transfected with siRNA against HO-1 ( Figure 5B ). This suggests a role of HO-1 in contributing to the anti-apoptotic phenotype of macrophages elicited by AC-CM (Weigert et al., 2006) .
To determine whether increased HO-1 expression also conveyed anti-inflammatory properties in our system, we analyzed the expression of three markers such as Adora HO-1 is induced in inflammatory macrophages to initiate an anti-inflammatory negative feedback loop, dependent on LPS-induced nitric oxide (NO) production (Ashino et al., 2008) . Thus, we investigated whether NO reproduced HO-1-depedent effects on gene expression in our system. Indeed, Deta-NO induced Adora A 2A , although induction was less pronounced compared to AC-CM (Figures 5, C and F).
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To examine which product of the HO-1-catalyzed reaction mediated Adora A 2A induction, bilirubin and the CO-releasing molecule CORM-2 were used. Both agents significantly elevated Adora A 2A mRNA expression ( Figure 5F ). However expression was low compared to the impact of AC-CM. Interestingly, the inactivated, i.e.
decomposed product of CORM-2 (iCORM-2) was without effect ( Figure 5F ).
Considering that iron chelators showed no effect on Adora A 2A mRNA expression (data not shown) excludes that ferrous iron, generated during heme degradation, is involved.
In conclusion, AC-CM caused expression of HO-1 in macrophages, which concomitantly evokes distinct anti-apoptotic as well as anti-inflammatory responses in these cells (Figure 6 ).
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DISCUSSION
Our data suggest that AC-derived S1P induces HO-1 expression in primary human macrophages, which in turn increases the amount of anti-apoptotic proteins such as Bcl-2 or Bcl-X L and Adora A 2A . The notion that authentic or AC-derived S1P induces HO-1 is in line with a report by Man and coworkers, showing that FTY720 enhanced HO-1 expression (Man et al., 2005) . Human macrophages express the S1P receptor subtypes 1 to 4 (Fueller et al., 2003) . Considering that activation of S1P 1 attenuated the expression of pro-inflammatory cytokines in mouse macrophages (Hughes et al., 2008) in conjunction with our previous observation that S1P 1 signaling in macrophages protected from apoptosis (Weigert et al., 2006) fits well with the present study, demonstrating that S1P 1 provoked an increase in HO-1 expression, which in turn triggered anti-apoptotic as well as anti-inflammatory signals. Inhibitor studies revealed that in primary human macrophages p38 MAPK, a pathway well known for HO-1 induction (Wijayanti et al., 2005; Kocanova et al., 2007) , facilitated S1P-evoked HO-1 expression. However, other studies have shown that p38 MAPK was also activated downstream of S1P 2 (Taha et al., 2004) , which might explain that siRNA-mediated knockdown of S1P 1 could not completely reduce HO-1 expression after stimulation with AC-CM, with the option that residual S1P 2 signaling occurred.
Our study suggests a crosstalk between S1P-signaling and VEGFA secretion from human macrophages. A connection between S1P and VEGF signaling was recently also put forward for ML-1 thyroid follicular cancer as well as human FRO anaplastic thyroid cancer cells (Balthasar et al., 2008) . Furthermore, VEGF secretion from epithelial cells after phagocytosis of AC was demonstrated (Golpon et al., 2004) , although neither signal cross talk between AC and epithelial cells nor signaling consequences have been fully understood. In our system there is evidence for a 21 soluble factor generated by AC, rather than cell-cell contacts or phagocytosis being required for VEGF secretion. A connection between S1P and VEGF signaling is highlighted, especially for models of tumor angiogenesis, proposing that tumorderived S1P stimulates VEGF formation in endothelial cells (Milstien and Spiegel, 2006; Sabbadini, 2006) . Macrophages, as cells in the tumor microenvironment, are critical players stimulating angiogenesis in a variety of human tumors, where they exhibit a pronounced M2 anti-inflammatory and anti-apoptotic phenotype. Our finding that VEGFA was not only secreted from macrophages in response to S1P, but also caused autocrine signaling to further induce HO-1, implies an important role of S1P in macrophage polarization, with particular relevance in the tumor setting. Besides mechanisms such as tumor hypoxia, the interaction of tumor-associated macrophages (TAMs) with dying tumor cells could then promote VEGFA release to stimulate tumor angiogenesis. Our unexpected observation of elevated S1P 1 expression following the treatment with AC-CM might also be attributed to autocrine VEGF, since S1P 1 expression was increased in bovine aortic endothelial cells following their exposure to authentic VEGF (Igarashi et al., 2003) .
VEGF expression was induced by S1P via STAT1. This finding is rather extraordinary as S1P receptor activation has not been linked to STAT signaling before. However, Src kinase activation downstream of a G-protein coupled receptor such as S1P 1 might be a missing communication link (Rivera and Olivera, 2007) , although mechanisms of Src activation in response to G protein coupled receptor agonists are not fully understood (Gutkind, 2000) . Src kinase activation is upstream of STAT signaling in human monocytes (Norkina et al., 2007) , and one could speculate that Src kinase links S1P receptor activation to STAT activation in our system. Strikingly, in rat aortic vascular smooth muscle cells, S1P-stimulated transactivation of STAT-coupled epidermal growth factor receptor and platelet-derived growth factor  receptor were Src-dependent (Tanimoto et al., 2004) .
STAT1/STAT3 heterodimer formation was necessary for the autocrine induction of HO-1 by VEGF, which was previously observed in chronic lymphocytic leukemia B cells . Furthermore, STAT1 and STAT3 were involved in hyperoxiainduced gene transcription of HO-1 in RAW 264.7 macrophages (Lee et al., 2000) .
Activation of STATs presumably plays an important role in establishing the M2 macrophage phenotype in the tumor setting, since STAT1 is constitutively active in TAM (Biswas et al., 2006) and its enhanced signaling properties mediate T cell deletion (Kusmartsev and Gabrilovich, 2005) . Also, STAT3 and STAT6 are believed to contribute to M2 macrophage polarization (Sica and Bronte, 2007) . According to suggestions by Zhang and colleagues, enhanced Bcl-2 and Bcl-X L expression by HO-1 could be attributed to CO (Zhang et al., 2003) , as shown in a murine model of ischemia-reperfusion. Generally, several anti-apoptotic effects attributed to HO-1 are thought to be CO-mediated (Ryter et al., 2002) . This might also apply to Adora A 2A , since overexpression of HO-1 as well as exposure of RAW264.7 macrophages to CO augmented Adora A 2A mRNA as well as protein level (Haschemi et al., 2007) . The rather marginal effect seen with CO and bilirubin in our experiments may open a further possibility that HO-1 translocates to the nucleus to bind to a transcription factor or a protein complex, resulting in enhanced transcription of Adora A 2A (Lin et al., 2007) . Adora A 2A agonists are capable of blocking the inflammatory potential of human macrophages, such as pathogen-stimulated NO, TNF- or IL-12 production (Hasko et al., 2007) , but also promote wound healing in disease states like diabetes (Montesinos et al., 1997) .
Interestingly, expression of the anti-inflammatory marker IDO was, at least in human macrophages exposed to AC-CM, HO-1-independent. Nevertheless, the principle finding that AC-CM augments expression of IDO is exciting. IDO catalyzes the ratelimiting step of tryptophane degradation. Kynurenine, one of the products of this reaction, affects proliferation as well as differentiation of helper T cells (Brusko et al., 2005; Munn and Mellor, 2007) . Likely, in an inflammatory environment the presence of AC might help to promote healing, once an inflammatory stimulus is eliminated, by modulating adaptive immune responses. This phenotype pattern is further corroborated by our finding that macrophages downregulate HLA-DMB in response to AC. Although it was reported that bilirubin, a degradation product of biliverdin, suppressed MHC II expression in endothelial cells (Wu et al., 2005) , we could not confirm that HLA-DMB expression was HO-1-dependent in macrophages. Despite these cell type differences, reduced expression of HLA-DMB and increased abundance of IDO favor an attenuated response of T H1 cells, which is important to progress from inflammation towards healing.
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Taken together, apoptotic cell supernatants provoked alternative activation in human macrophages, characterized by up-regulation of Bcl-2, Bcl-X L , Adora A 2A and IDO, but down-regulation of MHC II expression. The establishment of this antiinflammatory phenotype was in part dependent on the induction of HO-1 by ACderived S1P (Figure 6 ). Thus, targeting HO-1 and/or its downstream effectors could be a therapeutic approach to treat patients suffering from diseases linked to antiinflammatory macrophage polarization during e.g. the late immunosuppressive phase of sepsis (Hasko and Pacher, 2008) or in cancer (Mantovani et al., 2002) , since this would influence M2 macrophage viability as well their polarization. (F) Adora A 2A mRNA expression following treatment with Deta-NO, bilirubin or CORM-2. Primary human macrophages were incubated with 500 µM Deta-NO for 9 h, 10 µM bilirubin for 1 h or 100 µM CORM-2 for 24 h. Graphs display mean values  SEM of at least three independent experiments. Significant differences in mRNA expression are marked by asterisks (*) at P  0.05, (**) at P  0.01 and (***) at P  0.001. 
